Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease

Simon D, Tascilar K, Fagni F, Schmidt K, Krönke G, Kleyer A, Ramming A, Schönau V, Bohr D, Knitza J, Harrer T, Manger K, Manger B, Schett G (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

DOI: 10.1136/annrheumdis-2021-221554

Abstract

Objectives To test whether patients with immune-mediated inflammatory disease (IMIDs), who did not respond to two doses of the SARS-CoV-2 vaccine, develop protective immunity, if a third vaccine dose is administered. Methods Patients with IMID who failed to seroconvert after two doses of SARS-CoV-2 vaccine were subjected to a third vaccination with either mRNA or vector-based vaccines. Anti-SARS-CoV-2 IgG, neutralising activity and T cell responses were assessed at baseline and 3 weeks after revaccination and also evaluated seprarately in rituximab (RTX) and non-RTX exposed patients. Results 66 non-responders were recruited, 33 treated with RTX, and 33 non-exposed to RTX. Overall, 49.2% patients seroconverted and 50.0% developed neutralising antibody activity. Seroconversion (78.8% vs 18.2%) and neutralising activity (80.0% vs 21.9%) was higher in non-RTX than RTX-treated patients with IMID, respectively. Humoral vaccination responses were not different among patients showing positive (59.3%) or negative (49.7%) T cell responses at baseline. Patients remaining on mRNA-based vaccines showed similar vaccination responses compared with those switching to vector-based vaccines. Conclusions Overall, these data strongly argue in favor of a third vaccination in patients with IMID lacking response to standard vaccination irrespective of their B cell status.

Authors with CRIS profile

David Simon Department of Medicine 3 – Rheumatology and Immunology Koray Tascilar Department of Medicine 3 – Rheumatology and Immunology Filippo Fagni Department of Medicine 3 – Rheumatology and Immunology Katja Schmidt Department of Medicine 3 – Rheumatology and Immunology Gerhard Krönke Professur für Modulation von Immunantworten Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology Andreas Ramming Medizinische Fakultät Verena Schönau Department of Medicine 3 – Rheumatology and Immunology Johannes Knitza Department of Medicine 3 – Rheumatology and Immunology Thomas Harrer Professur für Innere Medizin mit dem Schwerpunkt Immundefizienz Bernhard Manger Professur für Rheumatologie und Klinische Immunologie Georg Schett Lehrstuhl für Innere Medizin III

How to cite

APA:

Simon, D., Tascilar, K., Fagni, F., Schmidt, K., Krönke, G., Kleyer, A.,... Schett, G. (2021). Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2021-221554

MLA:

Simon, David, et al. "Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease." Annals of the Rheumatic Diseases (2021).

BibTeX: Download